The Types classification of the PGE2 ELISA Kit market distinguishes between competitive inhibition kits, sandwich ELISA kits, and quantitative high‑sensitivity formats, each addressing distinct assay requirements. Competitive inhibition kits, accounting for roughly 45 % of kit revenues, rely on the displacement of a labeled PGE2 analogue and are favored in high‑throughput screening where cost efficiency is paramount. Sandwich ELISA kits, contributing about 35 % of sales, employ capture and detection antibodies to achieve superior specificity, making them the preferred choice for clinical sample analysis and longitudinal studies. Quantitative high‑sensitivity kits, representing the remaining 20 %, incorporate amplified signal detection (e.g., chemiluminescence) to reach sub‑pg/mL limits of detection, supporting research on low‑abundance prostaglandin signaling in neurobiology and early‑phase drug development. The proportional revenue distribution across these types underpins the overall market structure, and shifts in laboratory budgeting or assay automation trends can re‑balance the relative contributions over time. Emerging multiplex platforms that integrate PGE2 detection with cytokine panels are expected to increase demand for high‑sensitivity kits, potentially elevating their market share to above 30 % within the next five years.
